Patents Assigned to Institut Curie
-
Publication number: 20210024984Abstract: The present invention relates to an in vitro method for identifying and/or characterizing one or more mutations in a hotspot mutation sequence of at least one ESR1 target fragment from a DNA sample, said method comprising subjecting the DNA sample to a drop-off digital polymerase chain reaction (PCR) in the presence of a PCR solution comprising: a pair of primers suitable for amplifying an ESR1 target fragment; an oligonucleotide reference (REF) hydrolysis probe, labeled with a fluorophore, wherein said REF oligonucleotide probe is complementary to a wild-type sequence of the target fragment located outside of the hotspot mutation sequence; an oligonucleotide hotspot (HOTSPOT) hydrolysis probe, labeled with another fluorophore, wherein said oligonucleotide HOTSPOT probe is complementary to a wild-type sequence of the hotspot mutation sequence of the target DNA fragment.Type: ApplicationFiled: March 14, 2019Publication date: January 28, 2021Applicants: Universite de Versailles Saint-Quentin-en-Yvelines, Universite de Paris, Institut National de la Santé et de la Recherche Médicale, Institut CurieInventors: Marc-Henri Stern, Emmanuelle Jeannot, Charlotte Proudhon, Jean-Yves Pierga, François-Clément Bidard
-
Patent number: 10844367Abstract: The present invention relates to a method for improving an industrial yeast strain of industrial interest, particularly a sterile hybrid strain, without resorting to recombinant DNA techniques.Type: GrantFiled: November 29, 2013Date of Patent: November 24, 2020Assignees: INSTITUT CURIE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE PIERRE ET MARIE CURIE (PARIS 6), UNIVERSITE NICE SOPHIA ANTIPOLIS, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)Inventors: Alain Nicolas, Gianni Liti
-
Patent number: 10821114Abstract: The present invention relates to a new class of cephalosporin derivatives of formula (I), notably having CXCR4 receptor antagonist effect, useful as a therapeutic agent for treating cancer, in particular for treating breast cancer, lung cancer and uveal melanoma. The invention further relates to a pharmaceutical composition comprising a compound of formula (I) and an additional antitumor drug for treating cancer.Type: GrantFiled: April 2, 2015Date of Patent: November 3, 2020Assignees: INSTITUT CURIE, HARMONIC PHARMAInventors: Arnaud Sinan Karaboga, Violeta Isabel Perez-Nueno, Michel Souchet, Didier Decaudin
-
Patent number: 10821128Abstract: The present invention relates to the use of a DBait molecules by systemic routes without any combination with an endosomolytic agent.Type: GrantFiled: March 1, 2017Date of Patent: November 3, 2020Assignees: ONXEO, INSTITUT CURIE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALEInventors: Marie Dutreix, Nathalie Berthault
-
Patent number: 10806729Abstract: The present invention relates to a quinoline derivative of formula (I) or anyone of its pharmaceutically acceptable salt, or anyone of its metabolites, for use for treating or preventing a viral infection, in particular a HIV infection or a HIV-related condition in a patient; and then terminating said treatment when: the viral load is low or undetectable; and/or the level of CD4+ cell count is maintained or restored.Type: GrantFiled: February 19, 2016Date of Patent: October 20, 2020Assignees: ABIVAX, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT CURIE, UNIVERSITE DE MONTPELLIERInventors: Didier Scherrer, Aude Garcel, Noelie Campos, Jamal Tazi, Audrey Vautrin, Florence Mahuteau, Romain Najman, Pauline Fornarelli
-
Patent number: 10809261Abstract: The present invention pertains to the field of cancer prediction. Specifically, it relates to a method for predicting the risk of recurrence of bladder cancer in a subject after treatment of bladder cancer comprising the steps of determining the amount of at least one biomarker selected from the biomarkers shown in Table, and comparing the amount of said at least one biomarker with a reference amount for said at least one biomarker, whereby the risk of recurrence of bladder cancer is to be predicted. The present invention also contemplates a method for identifying a subject being in need of a further bladder cancer therapy. Encompassed are, furthermore, diagnostic devices and kits for carrying out said methods.Type: GrantFiled: May 8, 2017Date of Patent: October 20, 2020Assignees: DEUTSCHES KREBSFORSCHUNGSZENTRUM, INSTITUT CURIEInventors: Christoph Schröder, Harish Srinivasan, Jörg Hoheisel, François Radvanyi
-
Patent number: 10780435Abstract: Disclosed is a minifluidic device including a matrix, an elongated guiding duct embedded at least in part in the matrix, with at least one port to the outside of the matrix, a movable fiber at least partly contained in the guiding duct, and able to undergo within the guiding duct, and at least along some part of the fiber, at least one action selected among a sliding, or a deformation, or a rotation and at least one of the movable fiber or the guiding duct is elastic or is non linear along at least part of its length, or at least part of the matrix is elastic.Type: GrantFiled: July 22, 2016Date of Patent: September 22, 2020Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT CURIE, UNIVERSITE PIERRE ET MARIE CURIEInventors: Bastien Venzac, Ayako Yamada, Jean-Louis Viovy, Stephanie Descroix, Laurent Malaquin
-
Publication number: 20200291466Abstract: The invention relates to a method for detecting a mutation in a microsatellite sequence locus of a target fragment from a DNA sample, comprising subjecting said DNA sample to a digital polymerase chain reaction (PCR) in the presence of a PCR solution comprising: a pair of primers for amplifying said target fragment of the DNA sample including said microsatellite sequence; a first MS oligonucleotide (MS) hydrolysis probe, labeled with a first fluorophore, wherein said first MS oligonucleotide probe is complementary to a wild-type sequence including the microsatellite sequence; a second oligonucleotide reference (REF) hydrolysis probe, labeled with a second fluorophore, wherein said second oligonucleotide REF probe is complementary to a wild-type sequence of said target DNA fragment which does not include said microsatellite sequence. The invention also encompasses methods for the diagnosis and prognosis of cancer and a method for determining the efficacy of a cancer treatment.Type: ApplicationFiled: July 11, 2018Publication date: September 17, 2020Applicants: Institut Curie, Institut National de la Santé et de la Recherche Médicale, Universite de Versailles Saint-Quentin-en-YvelinesInventors: Charlotte PROUDHON, Amélie KASPEREK, Amanda BORTOLINI SILVEIRA, François-Clément BIDARD, Marc-Henri STERN
-
Patent number: 10765758Abstract: The present invention relates to an optimized in vivo delivery system with endosomolytic agents for nucleic acid of therapeutic interest conjugated to molecules facilitating endocytosis, in particular for use in the treatment of cancer.Type: GrantFiled: July 1, 2019Date of Patent: September 8, 2020Assignees: ONXEO, INSTITUT CURIE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUEInventors: Jian-Sheng Sun, Marie Dutreix, Maria Quanz
-
Patent number: 10767151Abstract: A device for cell culture, in particular of neuronal cells, including: a substrate defining a first microfluidic chamber to be seeded with a first cell culture, and at least a second microfluidic chamber, a fluidic interconnection system connecting the first and second chambers and enabling cellular extensions, in particular axons, to extend from one chamber to the other, wherein the interconnection system of the device is made so as to promote the progression of at least one first type of cellular extension, the first and second types of extension being different either due to the microfluidic chamber from which they originate, or due to the type of cell of which they constitute an extension.Type: GrantFiled: October 12, 2009Date of Patent: September 8, 2020Assignees: CNRS-DAE, INSTITUT CURIE, SORBONNE UNIVERSITEInventors: Jean-Louis Viovy, Jean-Michel Peyrin, Bernard Brugg, Laure Saias, Paul Gougis, Maeva Vignes
-
Patent number: 10752668Abstract: The invention relates to the regulated expression of a chimeric antigen receptor (CAR) within a lentiviral vector. The CAR comprises a hook-binding domain that interacts with a hook, preferably encoded by the same lentiviral vector, which prevents proper processing and release of the CAR to the cell membrane. The invention encompasses vectors, methods of making the vectors, and methods of using them, including medicinal uses. The vectors can be used for administration to humans to induce immune responses and to treat cancers and tumors.Type: GrantFiled: July 24, 2015Date of Patent: August 25, 2020Assignees: Theravectys, Institut Curie, Centre National de la Recherche Scientifique, Sorbonne Universite, Institut National de la Sante et de la Recherche Medicale (INSERM)Inventors: Sophie Agaugue, Lorenzo Tibaldi, Klervi Even-Desrumaux, Dmitry Trubetskoy, Franck Perez, Sebastian Amigorena, Cécile Bauche
-
Publication number: 20200247046Abstract: A microfluidic print head of a printer has a distal face, an injection channel, a suction channel, a groove, and a light source or an optical waveguide. The injection channel is configured to inject an ink onto a substrate and leads onto the distal face by an injection opening The suction channel is configured to suck up the ink and leads onto the distal face by a suction opening. The groove is defined on the distal face and into which the suction opening leads.Type: ApplicationFiled: August 3, 2018Publication date: August 6, 2020Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT CURIE, SORBONNE UNIVERSITEInventors: Laurent Malaquin, Jean Louis Viovy, Sandrine Souleille, Xavier Dollat, Victor Fournie
-
Publication number: 20200239444Abstract: A compound of formula (I): wherein A and A? independently represent a phenylene group or a pyridylene group; R2 is a hydrogen atom or a (C1-C4)alkyl group; R3 is a 2-pyridyl group, 3-pyridyl group, a 4-pyridyl group, a 2-pyrimidinyl group, a 4-pyrimidinyl group or a 5-pyrimidinyl group; R4 is a carbonyl group or a sulfonyl group; and R5 is a —NH—(CH2)a—NR6R7 group or a 4-methylpiperazinyl group, with a being an integer from 1 to 4, R6 and R7 representing independently a (C1-C4)alkyl group, or R6 and R7 together with the nitrogen atom to which they are linked forming a heterocycle group which is chosen among a 4-methylpiperazinyl group, a morpholino group, a pyrrolidinyl group and a piperidino group; or any one of its pharmaceutically acceptable salt.Type: ApplicationFiled: April 15, 2020Publication date: July 30, 2020Applicants: ABIVAX, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT CURIE, UNIVERSITE DE MONTPELLIERInventors: Pierre ROUX, Florence MAHUTEAU, Romain NAJMAN, Gilles GADEA, Jamal TAZI, Didier SCHERRER, Carsten BROCK, Nathalie CAHUZAC
-
Patent number: 10717724Abstract: The present invention relates to a compound of formula (I): wherein A and A? independently represent a phenylene group or a pyridylene group; R2 is a hydrogen atom or a (C1-C4)alkyl group; R3 is a 2-pyridyl group, 3-pyridyl group, a 4-pyridyl group, a 2-pyrimidinyl group, a 4-pyrimidinyl group or a 5-pyrimidinyl group; R4 is a carbonyl group or a sulfonyl group; and R5 is a —NH—(CH2)a—NR6R7 group or a 4-methylpiperazinyl group, with a being an integer from 1 to 4, R6 and R7 representing independently a (C1-C4)alkyl group, or R6 and R7 together with the nitrogen atom to which they are linked forming a heterocycle group which is chosen among a 4-methylpiperazinyl group, a morpholino group, a pyrrolidinyl group and a piperidino group; or any one of its pharmaceutically acceptable salt.Type: GrantFiled: April 5, 2018Date of Patent: July 21, 2020Assignees: ABIVAX, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT CURIE, UNIVERSITE DE MONTPELLIERInventors: Pierre Roux, Florence Mahuteau, Romain Najman, Gilles Gadea, Jamal Tazi, Didier Scherrer, Carsten Brock, Nathalie Cahuzac
-
Patent number: 10718770Abstract: The present invention relates to a method for screening a compound useful for treating or preventing a viral infection or a virus-related condition in an individual, comprising at least the steps of: a) determining the ability of a candidate compound to promote the interaction between CBP20 and CBP80 in a sample, and b) selecting the candidate compound that is determined to promote said interaction at step a). The present invention further relates to a method for screening a compound useful for treating or preventing a viral infection or virus-related condition in an individual, comprising at least the steps of: a) determining the ability of a candidate compound to interact with CBP20 or CBP80 in a sample, and b) selecting the candidate compound that is determined to interact with CBP20 or CBP80 at step a).Type: GrantFiled: February 19, 2016Date of Patent: July 21, 2020Assignees: ABIV AX, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT CURIE, UNIVERSITE DE MONTPELLIERInventors: Didier Scherrer, Aude Garcel, Noelie Campos, Jamal Tazi, Audrey Vautrin, Florence Mahuteau, Romain Najman, Pauline Fornarelli
-
Patent number: 10683284Abstract: The manufacture and use of compounds of formula (Ia) or a pharmaceutically acceptable salt thereof for preventing, inhibiting or treating cancer, AIDS and/or premature aging. The compounds of formula (Ia) being: where: R independently represents a hydrogen atom, a halogen atom, a (C1-C3)alkyl group, a —CN group, a hydroxyl group, a —COOR1 group, a (C1-C3)fluoroalkyl group, a —NO2 group, a —NR1R2 group, or a (C1-C3)alkoxy group; R? is a hydrogen atom, a halogen atom, a (C1-C3)alkyl group, a —NO2 group, a (C1-C3)alkoxy group, or a —NR1R2 group; and R1 and R2 are a hydrogen atom or a (C1-C3) alkyl group.Type: GrantFiled: July 31, 2018Date of Patent: June 16, 2020Assignees: ABIVAX, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE—CNRS, INSTITUT CURIE, UNIVERSITE DE MONTPELLIERInventors: Jamal Tazi, Florence Mahuteau, Romain Najman, Didier Scherrer, Julien Santo
-
Publication number: 20200172525Abstract: The present disclosure is generally directed to the manufacture and use of compounds described herein for preventing, inhibiting or treating cancer, AIDS and/or premature aging, or the manufacture and use of a pharmaceutical composition comprising at least one of the compounds, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier for preventing, inhibiting or treating cancer, AIDS and/or premature aging.Type: ApplicationFiled: February 11, 2020Publication date: June 4, 2020Applicants: ABIVAX, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT CURIE, UNIVERSITE DE MONTPELLIERInventors: Jamal TAZI, Florence MAHUTEAU, Romain NAJMAN, Didier SCHERRER, Julien SANTO
-
Publication number: 20200171499Abstract: A microfluidic device for performing physical, chemical or biological treatment to at least one packet without contamination.Type: ApplicationFiled: February 7, 2020Publication date: June 4, 2020Applicants: INSTITUT CURIE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUEInventors: Jean-Louis VIOVY, Max CHABERT, Kevin DORFMAN
-
Patent number: 10661274Abstract: Disclosed is a fluidic device including at least: a) a solid matrix; b) a textile component, embedded in the matrix and mechanically cohesive with the matrix; c) at least one channel embedded in the matrix and entangled with the textile component, the channel being at least partly open. A method for making a fluidic device includes providing a textile component including support fibers and at least a movable fiber entangled with the textile, embedding at least part of the textile and part of the movable fiber, in a matrix precursor material, applying a treatment in order to obtain a solid matrix.Type: GrantFiled: July 22, 2016Date of Patent: May 26, 2020Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT CURIE, UNIVERSITE PIERRE ET MARIE CURIEInventors: Jean-Louis Viovy, Bastien Venzac, Laurent Malaquin, Stephanie Descroix
-
Patent number: 10661278Abstract: A microfluidic device for performing physical, chemical or biological treatment to at least one packet without contamination.Type: GrantFiled: December 28, 2016Date of Patent: May 26, 2020Assignees: INSTITUT CURIE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUEInventors: Jean-Louis Viovy, Max Chabert, Kevin Dorfman